FTO is demonstrated to promote carcinogenesis and anti‐PD‐1 resistance in melanoma, suggesting that FTO could be a potential therapeutic target in immunotherapy,69 and the deletion of YTHDF1 enhances the therapeutic efficacy of PD‐L1 checkpoint blockade, indicating that the m6A‐binding protein YTHDF1 could be another therapeutic target in antitumour immunotherapy.70 This evidence concerns the gene METTL3 and melanoma.